Cost-effectiveness of screening of coronary artery disease in patients with type 2 diabetes at a very high cardiovascular risk (SCADIAB) study. Updated study design: emulation of a randomised target trial using electronic health records.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article discusses the Cost-effectiveness of Screening of Coronary Artery Disease in patients with type 2 diabetes at a very high cardiovascular risk (SCADIAB) study. The study aims to evaluate the cost-effectiveness of routine coronary artery disease (CAD) screening in patients with type 2 diabetes and a high cardiovascular risk. The study design involves the emulation of a randomized target trial using the French electronic health record system. The primary outcome of the study is the incremental cost per life-year gained over 4 years in the CAD screening group compared to the control group. The study protocol has been approved, and analysis is expected to be completed by the end of 2023. The results of the study will provide valuable insights for healthcare resource allocation and clinical decision-making. [Extracted from the article]
    • Abstract:
      Copyright of Cardiovascular Diabetology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)